UK Government commits to long-term R&D funding
The announcement supports the UK government’s broader plans for reformation of longer-term funding for the research and development sector.
List view / Grid view
The announcement supports the UK government’s broader plans for reformation of longer-term funding for the research and development sector.
EPR's latest Pharma Horizons report explores the latest advances in cell and gene therapy for quality control, manufacturing, analytical development and more.
12 May 2025 | By Mettler Toledo
Join this webinar to learn about impurity control in pharmaceutical waters, the differences between microbial and organic contaminants, and best practices for measurement and treatment.
The novel cell therapy utilises a shortened manufacturing process compared to standard production timelines, offering potential for enhanced therapeutic capability.
The biologic delivered sustained remission in adults with the inflammatory bowel disease (IBD) over the two-year study, results show.
With clinical data showing the gene therapy can address large and challenging chronic wounds, the FDA’s decision will help improve quality of life for dystrophic epidermolysis bullosa (DEB) patients.
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of a variety of new medicines, including several treatments for hereditary and rare conditions.
This article explores how artificial intelligence (AI) is forming an essential pillar of staying competitive in pharmaceutical manufacturing, with its adoption ensuring greater efficiency of medicine production in this fast-evolving sector.
25 April 2025 | By Rapid Micro Biosystems and ATCC
This webinar explores validation of rapid microbial methods with ready-to-use reference materials, a new industry standard in microbial QC testing.
The collaboration between Boehringer Ingelheim and Tessellate Bio seeks to address availability of targeted medicines for a cancer type shown to be difficult to treat.
The findings suggest that the biologic treatment could improve short-term outcomes for patients with lupus nephritis.
The US approval could improve outcomes for eligible patients with previously limited options for managing the inflammatory skin condition.
Youngsun Kim and Busol Park from Samsung Biologics detail the benefits of using a Quality-by-design approach for biologics manufacturing.
Subject to regulatory approval, the small molecule drug could provide a new treatment option for diabetes and obesity, Eli Lilly’s new data suggests.
Lecanemab is the only approved Aβ monoclonal antibody that highly binds to and clears toxic protofibrils with high selectivity.